secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001564590-22-018868
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Q1 2022 cash $98.7M; on track for registrational study in pulmonary sarcoidosis
--------------------------------------------------------------------------------

- Cash and investments $98.7M at March 31, 2022; R&D expenses $8.9M, G&A $3.5M.
- Phase 1b/2a efzofitimod data to be presented at ATS 2022; registrational study planned for Q3 2022.
- FDA orphan drug designation for efzofitimod in systemic sclerosis; exploring expansion into other ILDs.
- ATYR2810 IND candidate; Phase 1 study in cancer expected in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022018868/0001564590-22-018868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022018868/life-8k_20220509.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-018868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer